<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21054" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Emtricitabine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Muller</surname>
            <given-names>James T.</given-names>
          </name>
          <aff>Campbell University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Al Khalili</surname>
            <given-names>Yasir</given-names>
          </name>
          <aff>Virginia Commonwealth University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Muller declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasir Al Khalili declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21054.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine is used in combination with other antiretroviral therapy (ART) in the treatment of HIV-1, HIV-2, and hepatitis B virus (HBV). It is also used in combination therapy for pre-exposure prophylaxis (PrEP) to prevent HIV infection. Emtricitabine is FDA-approved for use in HIV treatment but is not FDA-approved for the treatment of HBV. This activity will highlight the mechanism of action, adverse event profile, pharmacology, monitoring, and relevant interactions of emtricitabine, pertinent for members of the interprofessional team in the treatment of patients with HIV or who require HIV prophylaxis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the mechanism of action of NRTIs including emtricitabine.</p></list-item><list-item><p>Identify the regimens for HIV treatment and prevention that use emtricitabine as a component.</p></list-item><list-item><p>Outline the need for monitoring and followup when prescribing antiretroviral therapy where emtricitabine is involved.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients when using ART, including with emtricitabine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21054&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21054">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21054.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Antiretroviral therapy (ART) has become the mainstay treatment for patients living with human immunodeficiency virus (HIV). The nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine is used in combination with other ART in the treatment of HIV-1, HIV-2, and hepatitis B virus (HBV).<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Emtricitabine is FDA-approved for use in HIV treatment but is not FDA-approved for the treatment of HBV.<xref ref-type="bibr" rid="article-21054.r2">[2]</xref>&#x000a0;One study showed that emtricitabine at 200 mg helped patients achieve lower HBV DNA load and helped patients achieve normal ALT.<xref ref-type="bibr" rid="article-21054.r3">[3]</xref>&#x000a0;For pregnant women with concurrent HIV infection, ART should commence as soon as possible.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;Options for ART available for pregnant women include the NRTI emtricitabine, along with abacavir, lamivudine, and tenofovir.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;Early administration of ART in pregnancy reduces the risk of transmitting HIV to the infant.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;Emtricitabine is a category B drug that does not cause teratogenesis or congenital abnormalities.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Emtricitabine safely treats patients with concurrent HIV and hepatitis C infection (HCV), as emtricitabine has few interactions with HCV medications.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;&#x000a0;</p>
        <p>The FDA-approved, combined drug, containing emtricitabine and tenofovir is used as pre-exposure prophylaxis (PrEP) to prevent HIV infection.<xref ref-type="bibr" rid="article-21054.r5">[5]</xref><xref ref-type="bibr" rid="article-21054.r6">[6]</xref>&#x000a0;Indications for PrEP use include someone who has sex with an HIV-positive individual, having sex with individuals of unknown HIV status and not being in a monogamous relationship, having a past sexually transmitted&#x000a0;infection within the prior six months, using condoms inconsistently in the past, and exchanging sex for money or other goods.<xref ref-type="bibr" rid="article-21054.r7">[7]</xref>&#x000a0;PrEP is also indicated for patients using intravenous drugs or entering into a drug rehabilitation program within the last six months.<xref ref-type="bibr" rid="article-21054.r7">[7]</xref>&#x000a0;The PROUD study tested the effectiveness of PrEP in HIV-negative men in clinics across England in 2013.<xref ref-type="bibr" rid="article-21054.r8">[8]</xref>&#x000a0;The PROUD study reduced the incidence of HIV by 86% in the PrEP group in a patient population where the rate of HIV was seven times greater than the population of men who have sex with men in the same clinics gathered from 2012.<xref ref-type="bibr" rid="article-21054.r8">[8]</xref></p>
        <p>Another indication for emtricitabine is as post-exposure prophylaxis (PEP) after possible exposure to HIV infection. Potential sources of HIV transmission include receptive anal intercourse, insertive anal intercourse, receptive vaginal intercourse, insertive vaginal intercourse, blood transfusion, needlestick injury, sharing needles among intravenous drug users, and mucous membrane exposure.<xref ref-type="bibr" rid="article-21054.r9">[9]</xref>&#x000a0;PEP administration should be within 72 hours of possible exposure, and the recommended duration is 28 days.<xref ref-type="bibr" rid="article-21054.r9">[9]</xref>&#x000a0;PEP therapy is similar to HIV therapy and includes the use of two NRTI&#x02019;s with an additional HIV mediation from a different category. The combination pill containing emtricitabine and tenofovir is a common therapeutic choice as a part of PEP therapy due to fewer side effects.<xref ref-type="bibr" rid="article-21054.r9">[9]</xref></p>
      </sec>
      <sec id="article-21054.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Emtricitabine, a cytosine analog that works as a nucleoside reverse transcriptase inhibitor (NRTI). The chemical structure is 5-Fluoro-1-[2R,5S)-2-(hydroxymethyl)-[1,3]oxathiolane-5-yl]cytosine (FTC).<xref ref-type="bibr" rid="article-21054.r3">[3]</xref>&#x000a0;It has a similar chemical structure to lamivudine.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Emtricitabine, like other NRTIs, is administered as a prodrug and needs to enter the host cell to be phosphorylated before imparting its antiviral effects.<xref ref-type="bibr" rid="article-21054.r10">[10]</xref>&#x000a0;Emtricitabine becomes phosphorylated into the active triphosphate form, emtricitabine 5&#x02019;-triphosphate, which incorporates into HIV reverse transcriptase of the viral DNA to prevent future HIV DNA synthesis.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Emtricitabine inhibits the formation of a 3&#x02019;-5&#x02019;-phosphodiester bond between the drug and the 5&#x02019;-nucleoside triphosphates of the HIV DNA chain leading to cessation of the growing HIV DNA chain.<xref ref-type="bibr" rid="article-21054.r10">[10]</xref>&#x000a0;In general, NRTIs work by blocking HIV from using reverse transcriptase, which will prevent the virus from converting its RNA into DNA. Without reverse transcriptase, HIV will be unable to replicate in the human body. Blocking reverse transcriptase helps to lower the HIV viral load and increase the CD4+ T-cell count.<xref ref-type="bibr" rid="article-21054.r7">[7]</xref>&#x000a0;Emtricitabine excretion is via the kidneys.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref></p>
      </sec>
      <sec id="article-21054.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Emtricitabine is typically administered orally once a day in combination with other antiretroviral therapy (ART).<xref ref-type="bibr" rid="article-21054.r11">[11]</xref>&#x000a0;Begin ART as soon as possible after an accurate diagnosis of HIV infection but within the first 14 days.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;The World Health Organization recommends initiating ART within seven days after diagnosis to decrease viral load.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;A three-drug regimen is a typical regimen for the initial treatment of HIV consisting of two nucleoside reverse transcriptase inhibitors (NRTIs) and an integrase inhibitor.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;The recommended initial regimens include combinations such as tenofovir, emtricitabine, and bictegravir or tenofovir, emtricitabine, and dolutegravir.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;In the setting of opportunistic infections, ART should commence within the first two weeks.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;The finding of malignancy in HIV patients constitutes immediate ART therapy.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref></p>
        <p>Emtricitabine has been studied at doses of 25 mg twice per day, 100 mg once daily, 100 mg twice daily, 200 mg once daily, and 200 mg twice per day.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;All doses studied led to a reduction in HIV viral load, with higher doses leading to more significant reductions.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Emtricitabine, combined with other ART, such as didanosine and efavirenz, led to an even more significant decrease in HIV viral loads and an increased CD4+ T-cell count.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Studies estimate that a 95% adherence to ART is needed to achieve undetectable viral loads and prevent drug-resistant HIV from emerging.<xref ref-type="bibr" rid="article-21054.r12">[12]</xref>&#x000a0;Proper adherence requires patients to take their HIV regimens every day precisely as prescribed by their physician.</p>
        <p>Emtricitabine (200 mg) and tenofovir (300 mg) used as pre-exposure prophylaxis are prescribed as a once-daily oral tablet.<xref ref-type="bibr" rid="article-21054.r13">[13]</xref></p>
      </sec>
      <sec id="article-21054.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of emtricitabine are similar to those of other nucleoside reverse transcriptase inhibitors (NRTIs) and include headache, muscle weakness, arthralgia, fatigue, fever, abdominal pain, nausea, vomiting, diarrhea, depression, anxiety, insomnia, rhinitis, cough, and pharyngitis.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref><xref ref-type="bibr" rid="article-21054.r11">[11]</xref>&#x000a0;More specifically, emtricitabine has shown an association with skin discoloration.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;This dermatologic effect presents as hyperpigmentation of the palms and soles, especially in African American patients.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Less commonly, skin discoloration can occur on the tongue, arms, lips, and nail beds.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Emtricitabine has not correlated with any serious adverse events.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;&#x000a0;</p>
        <p>Emtricitabine combined with tenofovir used as pre-exposure prophylaxis (PrEP) is safe with short-term use of about 2 to 3 years.<xref ref-type="bibr" rid="article-21054.r14">[14]</xref>&#x000a0;The common adverse effects associated with this combination include gastrointestinal symptoms, headache, nausea, and depression.<xref ref-type="bibr" rid="article-21054.r14">[14]</xref>&#x000a0;This combination has correlated with a decreased creatine clearance that improves with discontinuation of the drug.<xref ref-type="bibr" rid="article-21054.r14">[14]</xref>&#x000a0;PrEP can cause a decline in GFR initially, but this decline becomes more gradual the longer a person takes PrEP. PrEP was not associated with severe renal dysfunction, but a decreased GFR was a common presenting finding in patients over the age of 40.<xref ref-type="bibr" rid="article-21054.r15">[15]</xref>&#x000a0;This combination has also correlated with a decrease in bone mineral density that returned to normal levels with discontinuation of the drug.<xref ref-type="bibr" rid="article-21054.r14">[14]</xref>&#x000a0;Research has not shown the decline in bone mineral density to lead to increased fracture risk.<xref ref-type="bibr" rid="article-21054.r14">[14]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-21054.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients with an allergy to any constituent of emtricitabine should avoid taking this drug. Emtricitabine combined with tenofovir as pre-exposure prophylaxis (PrEP) is contraindicated as monotherapy for patients with a positive HIV status. This monotherapy can lead to HIV drug resistance to antiretroviral therapy (ART). Emtricitabine alone has not demonstrated any significant drug interactions.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;PrEP therapy is contraindicated in patients who have impaired renal function with a creatinine clearance of 60 mL/min.<xref ref-type="bibr" rid="article-21054.r7">[7]</xref>&#x000a0;PrEP treatment is also contraindicated in combination with high-dose NSAIDs, acyclovir, valacyclovir, cidofovir, and aminoglycosides.<xref ref-type="bibr" rid="article-21054.r7">[7]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-21054.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Emtricitabine, along with the other drugs in the nucleoside reverse transcriptase inhibitor (NRTI) category, interacts with mitochondrial DNA polymerase, causing myopathy and neuropathy.&#x000a0;This toxic interaction also has associations with hepatic steatosis and lactic acidosis.&#x000a0;Emtricitabine has not shown any adverse effects on the mitochondrial function of developing fetuses and is not known to be teratogenic.&#x000a0;There has been no evidence of emtricitabine affecting the fertility rates of women taking the drug.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-21054.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>HIV prevention and treatment are the responsibility of an integrated, interprofessional health team comprised of primary care physicians, physician assistants, nurse practitioners, specialty care physicians, nurses, office staff, pharmacists, and laboratory technicians. HIV prevention begins with health education on safer sex practices from the patient&#x02019;s primary care physician. The primary care providers need to be non-judgmental and well-versed in taking a detailed sexual history using open-ended questions, as well as asking all aspects of the social history, including alcohol and drug use.<xref ref-type="bibr" rid="article-21054.r16">[16]</xref>&#x000a0;Every time a patient comes to the primary care clinic, a risk evaluation of contracting HIV is necessary.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 5]&#x000a0;In addition to HIV testing discussions in the primary care setting, emergency departments and OB/GYN physicians should be offering routine testing.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 3]</p>
        <p>For high-risk individuals, the benefits of protection from daily pre-exposure prophylaxis (PrEP) can be discussed with patients. The daily PrEP recommended is a combination once-daily pill with emtricitabine and tenofovir. The patient should receive proper education from the primary providers, nurses, and pharmacists before prescribing and using PrEP. These guidelines include using PrEP consistently for one week before sexual activity to allow for adequate drug levels to build in rectal, penile, and vaginal tissue.&#x000a0;Patients should also receive reminders to continue PrEP for one week after the last sexual encounter if wanting to discontinue this medication.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 5] Nursing should repeat these educational points before the patient leaves to increase understanding of PrEP use. Before prescribing PrEP, HIV testing should take place for all patients, using an antigen-antibody assay to confirm the seronegative status.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 3]&#x000a0;Other recommendations before prescribing PrEP include measuring serum creatine, GFR, and HBsAg.&#x000a0;Patients should be seen at one month after starting PrEP to assess for side effects and adherence and every three months to perform repeat HIV testing.&#x000a0;Additional antiretroviral therapy (ART) should be initiated if there is a diagnosis of HIV while a patient is on PrEP.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 5]&#x000a0;Hepatitis C virus (HCV) should be tested annually for those on PrEP therapy.&#x000a0;Creatinine measurements should be performed every six months and more often for patients concurrently taking hypertension or diabetes medications, those over the age of 50, and those with a GFR less than 90 mL/min.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 3]&#x000a0;Every subsequent visit while on PrEP should be used to discuss safe sex measures such as condom use and daily adherence to the medication. Any patient with hepatitis B virus (HBV) who is taking PrEP that includes emtricitabine requires close monitoring if discontinuing the medication due to liver damage from reactivation of the HBV.<xref ref-type="bibr" rid="article-21054.r16">[16]</xref>&#x000a0;</p>
        <p>Every patient should receive an HIV test at least once&#x000a0;in their lives, with specific populations needing more frequent testing.&#x000a0;Men having sex with men, transgender women, and intravenous drug users should have HIV testing at least one time per year and as frequently as every three months.&#x000a0;Patients who present with sexually transmitted&#x000a0;infections and HCV should be screened for HIV more often.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 5<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;When testing for HIV, the health care team needs to explain how HIV testing methodology, how long until the results return, and that they must report positive results to the state health department.<xref ref-type="bibr" rid="article-21054.r17">[17]</xref>&#x000a0;HIV testing recommendations include combination antibody-antigen assay or combination antibody assay with nucleic acid testing.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 3]&#x000a0;Further testing of the HIV viral load is the recommendation before prescribing ART.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 1]&#x000a0;Patients found to be HIV-positive need a referral to infectious disease or an HIV specialist. Further testing of HIV viral load and HIV genotype should take place before prescribing ART. HIV genotype testing before medical therapy shows which medications the specific strain of HIV may have resistance.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 5]&#x000a0;The comorbidities of these patients need to be documented well in the electronic health record, especially if the patient has concurrent HBV. Liver enzymes and HBV DNA viral load become elevated when a patient stops taking emtricitabine abruptly.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;Primary care and infectious disease providers need to monitor the patient for signs of liver damage for weeks after discontinuing emtricitabine.<xref ref-type="bibr" rid="article-21054.r1">[1]</xref>&#x000a0;It is also essential for a health care provider to address the mental health of a newly diagnosed HIV patient and those living with HIV, with referral to psychiatry or counseling a possibility. The health care team must keep track of when their patients receive their medications, and when they come to their appointments.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 3]<xref ref-type="bibr" rid="article-21054.r4">[4]</xref>&#x000a0;The entire office, including the front desk administration, can assist with reminding patients of appointments and follow-ups.<xref ref-type="bibr" rid="article-21054.r4">[4]</xref> [Level 1]&#x000a0;Every visit presents an opportunity to discuss adherence to ART, screen for an understanding of medications, and reiterate the importance of safe sex practices and honesty of diagnosis for those with HIV. Screening the social factors of this patient population is vital to guarantee these patients can afford their medications, understand how to take their medications, have support from family and friends, and have access to proper transportation to and from the physician&#x02019;s office. It may be necessary to bring in a social worker to help further address the social needs of this patient population.</p>
        <p>Finally, it is the responsibility of health care providers to advertise the short-term use of drugs like emtricitabine in combination with other HIV medications as post-exposure prophylaxis (PEP).<xref ref-type="bibr" rid="article-21054.r9">[9]</xref>&#x000a0;Patients should be made aware of HIV exposure risks and when and how to seek therapy. Protocols should be in place by physician&#x02019;s offices and hospitals for possible HIV exposure. This protocol includes determining the HIV status of the patient who is requesting PEP therapy and the HIV status of the subject with whom the patient was in contact with if possible.<xref ref-type="bibr" rid="article-21054.r9">[9]</xref>&#x000a0;One should also assess the timing and frequency of HIV exposure, the risk of exposure, and the possibility for other sexually transmitted infections.<xref ref-type="bibr" rid="article-21054.r9">[9]</xref>&#x000a0;Finally, it is essential to educate the patient on safe sex and how to reduce occupational exposures and follow up to determine adherence to the therapy and side effects with the treatment.<xref ref-type="bibr" rid="article-21054.r9">[9]</xref>&#x000a0;Patients requesting PEP should be evaluated by a health care worker that can stratify risk factors and determine whether the patient&#x02019;s exposure needs ART. PEP therapy should be readily available to all health care workers, along with laboratory testing in the case of occupational exposure. Testing for occupation therapy should be promoted and simplified, so health care workers can feel comfortable coming forward to protect their health.</p>
      </sec>
      <sec id="article-21054.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21054&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21054">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21054/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21054">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21054.s10">
        <title>References</title>
        <ref id="article-21054.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.</article-title>
            <source>Clin Infect Dis</source>
            <year>2006</year>
            <month>Jan</month>
            <day>01</day>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>126</fpage>
            <page-range>126-31</page-range>
            <pub-id pub-id-type="pmid">16323102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherman</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Management of the Hepatitis B Virus/HIV-Coinfected Patient.</article-title>
            <source>Top Antivir Med</source>
            <year>2015</year>
            <season>Aug-Sep</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>111</fpage>
            <page-range>111-4</page-range>
            <pub-id pub-id-type="pmid">26518394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gish</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Fried</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mondou</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Snow</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sorbel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corey</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection: a two-year study.</article-title>
            <source>J Hepatol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-6</page-range>
            <pub-id pub-id-type="pmid">15922478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saag</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Hoy</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Landovitz</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Mugavero</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sax</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Buchbinder</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Del Rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>F&#x000e4;tkenheuer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>G&#x000fc;nthard</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Molina</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Volberding</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Jul</month>
            <day>24</day>
            <volume>320</volume>
            <issue>4</issue>
            <fpage>379</fpage>
            <page-range>379-396</page-range>
            <pub-id pub-id-type="pmid">30043070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krakower</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.</article-title>
            <source>Drugs</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-51</page-range>
            <pub-id pub-id-type="pmid">25673022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buchbinder</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>Maximizing the Benefits of HIV Preexposure Prophylaxis.</article-title>
            <source>Top Antivir Med</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>138</fpage>
            <page-range>138-142</page-range>
            <pub-id pub-id-type="pmid">29689539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marfatia</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Jose</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Baxi</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pre- and post-sexual exposure prophylaxis of HIV: An update.</article-title>
            <source>Indian J Sex Transm Dis AIDS</source>
            <year>2017</year>
            <season>Jan-Jun</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">28442797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolling</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McOwan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gilson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schembri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mackie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Portman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bayley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bowman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lacey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Antonucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gafos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gill</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Nardone</surname>
                <given-names>A</given-names>
              </name>
              <collab>PROUD Study Group</collab>
            </person-group>
            <article-title>An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.</article-title>
            <source>Trials</source>
            <year>2016</year>
            <month>Mar</month>
            <day>24</day>
            <volume>17</volume>
            <fpage>163</fpage>
            <pub-id pub-id-type="pmid">27013513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Benn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Current perspectives in HIV post-exposure prophylaxis.</article-title>
            <source>HIV AIDS (Auckl)</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>147</fpage>
            <page-range>147-58</page-range>
            <pub-id pub-id-type="pmid">25368534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arts</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hazuda</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>HIV-1 antiretroviral drug therapy.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>a007161</fpage>
            <pub-id pub-id-type="pmid">22474613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <article-title>Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.</article-title>
            <source>Prescrire Int</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>76</issue>
            <fpage>54</fpage>
            <page-range>54-6</page-range>
            <pub-id pub-id-type="pmid">15875341</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chesney</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Adherence to HAART regimens.</article-title>
            <source>AIDS Patient Care STDS</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>169</fpage>
            <page-range>169-77</page-range>
            <pub-id pub-id-type="pmid">12737640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coutinho</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Emtricitabine/tenofovir (Truvada) for HIV prophylaxis.</article-title>
            <source>Am Fam Physician</source>
            <year>2013</year>
            <month>Oct</month>
            <day>15</day>
            <volume>88</volume>
            <issue>8</issue>
            <fpage>535</fpage>
            <page-range>535-40</page-range>
            <pub-id pub-id-type="pmid">24364575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Field</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grant</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCormack</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in pre-exposure prophylaxis for HIV.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>Dec</month>
            <day>11</day>
            <volume>359</volume>
            <fpage>j5011</fpage>
            <pub-id pub-id-type="pmid">29229609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drak</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barratt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Templeton</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Gracey</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.</article-title>
            <source>PLoS One</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>e0210106</fpage>
            <pub-id pub-id-type="pmid">30653509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krakower</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Top Questions in ID: Pre-exposure Prophylaxis for HIV.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2017</year>
            <season>Fall</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>ofx185</fpage>
            <pub-id pub-id-type="pmid">29026872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21054.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rizza</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>MacGowan</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Purcell</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Branson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Temesgen</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>HIV screening in the health care setting: status, barriers, and potential solutions.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>87</volume>
            <issue>9</issue>
            <fpage>915</fpage>
            <page-range>915-24</page-range>
            <pub-id pub-id-type="pmid">22958996</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
